Option chain shows key data for Aditxt's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aditxt.

Aditxt (NASDAQ:ADTX) Stock, Option Chain

Aditxt

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

APTO

BMBL

CYCU

DSGN

INNV

MGOL

MOVE

NEXA

NIVF

OSRH

RSLS

SINT

SUPN

THRM

TRUG

Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Stock Movers

CSAI

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MTRX

NESR

NTIC

TNMG

Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket

oil rig

Earnings

Equities

Eurozone

Commodities

EGRX

JOBY

Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings

Aditxt Inc

Small Cap

Press Releases

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Stocks Under $1: PMAX PRSO ARBB KAVL to Watch in March 2025 – More Stocks Inside

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves

AIBT

APLIF

ARBB

CBDW

CMND

CSDX

EVFM

KAVL

PMAX

PRSO

SIGL

SPRC

STSS

TSX:APLI

TSXV:YGT

VRPX

YGTFF

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptevo Therapeutics

180 Life Sciences

Azitra

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Galecto

GRI Bio

GT Biopharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Moleculin Biotech

Oragenics

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Polyrizon

Sunshine Biopharma

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Theriva Biologics

Xenetic Biosciences

HC Wainwright & Co.

Comments

Aditxt

Aditxt (ADTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga